Please Wait
Applying Filters...
menu
    • menu
    As a CDMO, Mikart offers integrated CDMO services for Solid Dose & Non-sterile Liquid formulations.

    Virtual Booth

    Contact Supplier

    LEBSA- Your strategic API source for niche molecules.

    Virtual Booth

    Contact Supplier

    Inke S.A: APIs manufacturing plant.

    Virtual Booth

    Contact Supplier

    Polpharma is a Polish CDMO of APIs and a significant European API producer, delivering products to companies worldwide.

    Virtual Booth

    Contact Supplier

    EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Virtual Booth

    Contact Supplier

    jdmfs-not-supported-m-2025-08-11

    Virtual Booth

    An Enquiry

    Menu

    Ixazomib Citrate

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    DRUG PRODUCT COMPOSITIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    PharmaCompass
    $ API Ref.Price (USD/KG) : 780,528Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Ixazomib Citrate API: A Weapon for Multiple Myeloma Treatment
    Ixazomib Citrate API: A Weapon for Multiple Myeloma Treatment

    15 Jul 2024

    // PRESS RELEASE

    https://www.qingmupharm.com/ixazomib-citrate-api-a-weapon-for-multiple-myeloma-treatment

    PRESS RELEASE
    15 Jul 2024
    Share Share
    Ixazomib Citrate API in the Age of Biosimilars
    Ixazomib Citrate API in the Age of Biosimilars

    04 Jun 2024

    // PRESS RELEASE

    https://www.qingmupharm.com/ixazomib-citrate-api-in-the-age-of-biosimilars

    PRESS RELEASE
    04 Jun 2024
    Share Share
    NICE recommends Takeda’s Ninlaro triplet regimen
    NICE recommends Takeda’s Ninlaro triplet regimen

    20 Jan 2023

    // PHARMATIMES

    https://www.pharmatimes.com/news/nice_recommends_takedas_ninlaro_triplet_regimen_1485592

    PHARMATIMES
    20 Jan 2023
    Share Share
    NICE recommends all-oral treatment for multiple myeloma
    NICE recommends all-oral treatment for multiple myeloma

    19 Jan 2023

    // EUROPEAN PHARMACEUTICAL REVIEW

    https://www.europeanpharmaceuticalreview.com/news/178699/nice-recommends-ixazomib-all-oral-treatment-for-multiple-myeloma/

    EUROPEAN PHARMACEUTICAL REVIEW
    19 Jan 2023
    Share Share
    Active Biotech Begins Dosing in comb. part of phase Ib/IIa study of tasquinimod
    Active Biotech Begins Dosing in comb. part of phase Ib/IIa study of tasquinimod

    07 Feb 2022

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2022/02/07/2379644/0/en/Active-Biotech-announces-first-patient-dosed-in-the-combination-part-of-the-phase-Ib-IIa-study-of-tasquinimod-in-multiple-myeloma.html

    GLOBENEWSWIRE
    07 Feb 2022
    Share Share
    Takeda Announces Result of Phase 3 Clinical Trial to Evaluate NINLARO (ixazomib)
    Takeda Announces Result of Phase 3 Clinical Trial to Evaluate NINLARO (ixazomib)

    11 Sep 2020

    // BUSINESS WIRE

    https://www.businesswire.com/news/home/20200910006063/nl

    BUSINESS WIRE
    11 Sep 2020
    Share Share